Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal

@article{Tosh2013GolimumabFT,
  title={Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal},
  author={Jonathan C Tosh and Rachel J Archer and Sarah Davis and M. D. Stevenson and John W Stevens},
  journal={PharmacoEconomics},
  year={2013},
  volume={31},
  pages={653-661}
}
As part of the National Institute for Health and Clinical Excellence (NICE) single technology appraisal (STA) process, the manufacturer of golimumab (Simponi®; Merck Sharp & Dohme, USA) was invited to submit evidence for its clinical and cost effectiveness for the treatment of rheumatoid arthritis (RA) after the failure of previous disease-modifying antirheumatic drugs (DMARDs). The School of Health and Related Research Technology Appraisal Group (ScHARR-TAG) at The University of Sheffield was… Expand
Golimumab for the Treatment of Psoriatic Arthritis
TLDR
The manufacturer’s own model showed that golimumab was unlikely to be cost effective, relative to currently accepted thresholds, when the ICERs were correctly calculated using an incremental analysis, and the ERG concluded that if all biologics were considered equally effective, they should be treated as a class. Expand
Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal
TLDR
The ERG found some problems with the CEA model, mainly that it did not allow for comparison of TNF-α inhibitor sequences and did not use MTC estimates for treatment discontinuation or adverse events (AEs). Expand
Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
TLDR
The ERG amended the manufacturer’s model and demonstrated that rituximab was likely to represent a cost-effective addition to the treatment sequence if given after cyclophosphamide treatment, and is superior to oral cycloph phosphate in terms of remission in adults who have relapsed once on cycloph phosphamide. Expand
Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma
TLDR
The Appraisal Committee concluded that pazopanib should be recommended as a first-line treatment option for people with advanced renal cell carcinoma who have not received prior cytokine therapy and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Expand
Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal
TLDR
It is concluded that ruxolitinib appears to reduce splenomegaly and its associated symptoms, but that there was considerable uncertainty surrounding the manufacturer’s cost-effectiveness estimates due to limitations in the manufacturer's model. Expand
Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal
TLDR
The NICE Appraisal Committee gave a negative initial recommendation, although indicated that trabectedin in aMSTS met the end-of-life criteria, and the ERG concluded that there was still considerable uncertainty in the ICER. Expand
The Added Value of Real-World Evidence
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost-effectiveness of the drug for treatingExpand
A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis
TLDR
The results show that evidence of cost–effectiveness was not equally perceived by decision makers and did not have equal weightage in defining the official listing of biologic DMARDs for the treatment of RA. Expand
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales
TLDR
Current NICE guidelines for the treatment of RA are overviewed and the use of tocilizumab or abatacept as the most appropriate treatments for some patients are considered. Expand
Golimumab: A Review in Inflammatory Arthritis
TLDR
Golimumab is an effective, generally well tolerated and potentially convenient option for the treatment of RA, PsA, AS and nr-axSpA in adults, and pJIA in children. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 73 REFERENCES
Golimumab for the Treatment of Psoriatic Arthritis
TLDR
The manufacturer’s own model showed that golimumab was unlikely to be cost effective, relative to currently accepted thresholds, when the ICERs were correctly calculated using an incremental analysis, and the ERG concluded that if all biologics were considered equally effective, they should be treated as a class. Expand
Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal
TLDR
The ERG found some problems with the CEA model, mainly that it did not allow for comparison of TNF-α inhibitor sequences and did not use MTC estimates for treatment discontinuation or adverse events (AEs). Expand
Febuxostat for the Management of Hyperuricaemia in Patients with Gout
TLDR
The NICE Appraisal Committee concluded that febuxostat be recommended as an option for the management of chronic hyperuricaemia in gout only for people who are intolerant to allopurinol or for whom allopURinol is contraindicated. Expand
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
TLDR
All three agents, either alone (where so licensed) or in combination with ongoing disease-modifying antirheumatic drugs (DMARDs), were effective in reducing the symptoms and signs of RA in patients with established disease. Expand
Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma
TLDR
The Appraisal Committee concluded that pazopanib should be recommended as a first-line treatment option for people with advanced renal cell carcinoma who have not received prior cytokine therapy and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Expand
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
TLDR
Evidence from RCTs suggests that RTX and ABT are more effective than supportive care, and the ICER for ABT compared with RTX is over £100,000 (per QALY); however, there remain uncertainties in the TNF inhibitors' effectiveness and cost-effectiveness. Expand
Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal
TLDR
The NICE Appraisal Committee gave a negative initial recommendation, although indicated that trabectedin in aMSTS met the end-of-life criteria, and the ERG concluded that there was still considerable uncertainty in the ICER. Expand
Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
TLDR
The analysis concludes that current policies and practice for the use of TNF-� antagonist therapies, after RA patients have failed at least two traditional disease-modifying anti-rheumatic drugs, appear cost-effective in the context of the NICE re-appraisal of 2006 for England and Wales, thus supporting their decision to continue their reimbursement. Expand
UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug
TLDR
Rituximab has lower average annual treatment costs compared to other bDMARDs and is a highly cost-effective treatment option for patients who have failed to respond adequately to one b DMARD. Expand
Alitretinoin for Severe Chronic Hand Eczema
TLDR
The ERG concluded that, although the evidence presented indicates that alitretinoin is efficacious in the treatment of severe CHE, it gives little indication of alit retinoin’s efficacy relative to likely alternative treatment options or its efficacy and safety in the longer term. Expand
...
1
2
3
4
5
...